Table 2 Clinical outcomes after filter insertion
Rivaroxaban group | Warfarin group | P value | |
|---|---|---|---|
Filter complications | |||
Symptomatic filter thrombosis | 4(3.5%) | 5(5.7%) | 0.690 |
TrapEase filter | 0 | 2 | |
OptEase filter | 3 | 1 | |
G2 filter | 0 | 1 | |
Aegisy filter | 1 | 1 | |
Other complications | 2(1.8%) | 2(2.3%) | 1.000 |
Time to symptomatic filter thrombosis | |||
Mean days (SD) | 439.3(214.9) | 369.8(245.3) | 0.624 |
Median | 462.0 | 308.0 | |
Q1, Q3 | 223.8, 632.0 | 164.5, 606.0 | |
Recurrent VTE | |||
Total | 2(1.8%) | 4(4.6%) | 0.407 |
DVT | 2(1.8%) | 3(3.4%) | 0.655 |
PE | – | 1(1.1%) | |
Deaths | |||
Total | 9(7.9%) | 8(9.1%) | 0.761 |
VTE-related | 0 | 1(1.1%) | |
Cancer-related | 5(4.4%) | 4(4.5%) | 1.000 |
Others | 4(3.5%) | 3(3.4%) | 1.000 |
Safety outcomes | |||
Total | 5(4.4%) | 14(15.9%) | 0.005 |
Major bleeding | 1(0.9%) | 2(2.3%) | 0.581 |
CRNM bleeding | 4(3.5%) | 12(13.6%) | 0.008 |